We are now into our 4th year of this magical mystery development and option agreement with AstraZeneca. I wonder how much money the Starpharma boffins have spent so far with no disclosed results or progress.
I also wonder if this option agreement will ever be executed or if not, disclosed to the market that it’s dead and buried. Based on previous form shareholders will never find out and instead this promising announcement will just drift off into the sunset without any accountability from CEO Jackie Fairley.
Someone was not surprisingly very bullish on this option agreement but we don’t tend to hear much anymore. Must be really close now …
3/6/19 Development option agreement signed.
17/2/20 ”Completion of pre-clinical is less than 12 months from June 2019........so within the next 4.5 months” ~@antibotter
21/2/20 ”We could have an answer before June 2020” ~@antibotter
01/11/20 ”Should not be long before we have disclosure” ~@antibotter
08/4/21 ”We will know sometime this calendar year ....if indeed faslodex is the undisclosed drug AstraZeneca has given permission for Starpharma to do research on” ~@antibotter
23/08/21 ”Starpharma must be so close to completion of pre clinical trials with an undisclosed AstraZeneca molecule” ~@antibotter
14/6/22 Still nothing to come of this magical mystery agreement, yet….
P.S. Just remember that it’s not all in vain if nothing eventuates from this, because the mere signing of an option agreement would have triggered a positive KPI in Jackie Fairley’s remuneration package. Bless.
SPL Price at posting:
70.5¢ Sentiment: None Disclosure: Not Held
